| Literature DB >> 35987940 |
Ghislain Rocheleau1,2, Iain S Forrest1,2,3, Áine Duffy1,2, Shantanu Bafna1, Amanda Dobbyn1,2,4, Marie Verbanck5, Hong-Hee Won6, Daniel M Jordan1,2, Ron Do7,8.
Abstract
Phenome-wide association studies identified numerous loci associated with traits and diseases. To help interpret these associations, we constructed a phenome-wide network map of colocalized genes and phenotypes. We generated colocalized signals using the Genotype-Tissue Expression data and genome-wide association results in UK Biobank. We identified 9151 colocalized genes for 1411 phenotypes across 48 tissues. Then, we constructed bipartite networks using the colocalized signals in each tissue, and showed that the majority of links were observed in a single tissue. We applied the biLouvain clustering algorithm in each tissue-specific network to identify co-clusters of genes and phenotypes. We observed significant enrichments of these co-clusters with known biological and functional gene classes. Overall, the phenome-wide map provides links between genes, phenotypes and tissues, and can yield biological and clinical discoveries.Entities:
Mesh:
Year: 2022 PMID: 35987940 PMCID: PMC9392744 DOI: 10.1038/s42003-022-03820-z
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642
Fig. 1Flowchart of the study.
The flowchart illustrates all the different steps of our study. GWAS genome-wide association study, GTEx Genotype-Tissue Expression, eQTL expression quantitative trait locus.
Fig. 2Characteristics of biLouvain co-clusters across tissues.
a Number of genes and phenotypes per co-cluster identified by the biLouvain algorithm. Diamonds are proportional to the frequency of co-cluster size across all 48 tissues. Both axes are displayed on the log scale. b Number of unique co-clusters and how many times they appear in a given number of tissues. y axis is displayed in log scale.
Fig. 3PANTHER enrichment analysis of selected biLouvain co-clusters across tissues.
Each panel represents a PANTHER annotation type: (a) Biological process; (b) Cellular component; (c) Molecular function; and (d) Pathway. In each panel, the observed minimal P value across all GO terms is plotted against the expected minimal P value under the null hypothesis of no enrichment for all 183 co-clusters selected. Some plots (a–c) show a breakdown in the y axis to help display very small P values.
Selection of interesting co-clusters in relevant tissues.
| Co-cluster/tissue | Nb of phenos | Nb of genes | Phenotype‡ | Gene | Biological function summary |
|---|---|---|---|---|---|
| Co-cluster 111† /cells—EBV - transformed lymphocytes | 4 | 13 | Hypothyroidism/myxedema | Med: levothyroxine sodium | ||
| Co-cluster 161 /heart-left ventricle | 6 | 12 | Angina pectoris | Ischemic heart disease (chronic, other) | Coronary atherosclerosis | Acute pain | Abnormal clotting and cardiac defect are associated with ischemic heart disease. | |
| Co-cluster 27 /adipose– subcutaneous | 11 | 18 | High cholesterol | Hayfever/allergic rhinitis | Breast cancer | Diabetes (Type 1, Type 2) | Diabetic retinopathy | Illness mother: diabetes | Med: metformin | ||
| Co-cluster 128 /thyroid | 4 | 12 | Nontoxic goiter (uninodular, multinodular, other) | ||
| Co-cluster 39 /artery-tibial | 15 | 10 | Angina (unstable) | Myocardial infarction | Ischemic heart disease (chronic) | Illness father: heart disease | Migraine/Headache | Med: ibuprofen, paracetamol | Migraine medications associated with increased risk of heart attack. | |
| Co-cluster 43/cells - transformed fibroblasts | 13 | 11 | Asthma | Hayfever/allergic rhinitis | Eczema/dermatitis | Wheezing/whistling | Med: ventolin, seretide | Nasal polyps | ||
| Co-cluster 11/whole blood | 32 | 14 | Angina (pectoris, unstable) | Ischemic HD (chronic, other) | MI | Coronary atherosclerosis | Illness father: HD, high BP | Illness mother: high BP | Father’s age at death | Hyperlipidemia/hypercholesterolemia | Med: simvastatin, atenolol, aspirin, lipitor, atorvastatin, ezetimibe |
Nb number, HD heart disease, MI myocardial infarction, BP blood pressure, Med medication, LDL-C low-density lipoprotein cholesterol, CAD coronary artery disease.
†Co-cluster most significant in PANTHER Pathway annotation.
‡For the sake of simplification, we grouped phenotypes with similar names in UKBB and/or matching ICD-10 codes and PheCodes.